Skip to main content

Table 2 Baseline characteristics

From: A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

 

n

%

Gender

 Male

8

57.1

 Female

6

42.9

Race/ethnicity

 Non-Hispanic White

9

64.3

 African American

2

14.3

 Hispanic

3

21.4

Age, years

 Median (SD)

65.0 (9.3)

 

 Range

52—81

 

ECOG performance status

 0

4

28.6

 1

10

71.4

Primary tumor

 Melanoma

3

21

 NSCLC

3

21

 Renal

2

14

 Bladder/urothelial

2

14

 Ovary

1

7

 Pleural mesothelioma

1

7

 Adenoid cystic

1

7

 Head and neck

1

7